01 December 2008
Point-of-care testing for interleukin-6 in cerebro spinal fluid (CSF) after subarachnoid haemorrhage
Julius DenglerBCDEF, Joerg C. SchefoldCDEF, Daniela GraetzBCD, Christian MeiselCDEFG, Gerald SplettstößerCDE, Hans-Dieter VolkCDEFG, Hans-Georg SchlosserABCDEFMed Sci Monit 2008; 14(12): BR265-268 :: ID: 869473
Abstract
Background
Intrathecal interleukin (IL)-6 is considered to be a proinflammatory biomarker for cerebral inflammatory response. This is of clinical importance for the prediction of vasospasm after subarachnoid haemorrhage (SAH). We evaluated a bedside technique for the quantitative measurement of IL-6 in the cerebrospinal fluid (CSF).
Material and Method
32 samples of CSF and serum were taken from 11 patients suffering from SAH on day 3, 4 and 5 after bleeding. A lateral flow immunoassay chip-test (POC-Test) was used for bedside testing and the results were compared to the standard chemiluminescence-based ELISA (Immulite) performed in a specialized laboratory.
Results
For CSF analysis Immulite and POC-Test show linear correlation (r2=0.81). The high IL-6 values found in SAH are depicted more easily by the POC-Test, because it has a working range of up to 10.000 pg/ml instead of up to 1000 pg/ml for Immulite. Serum IL-6 values were clearly lower, suggesting CNS inflammation in SAH.
Conclusions
The new chip-test provides a handy tool for the neurosurgical intensive care unit, analysing CSF IL-6 concentrations within 20 minutes. This is the first time a point-of care test for IL-6 in CSF was evaluated. The test results match the values achieved by the standard Immulite technique. Therefore a tool for clinical routine interleukin-6 investigation is provided which could find use in a broad variety of neurosurgical and neurological diseases.
Keywords: Subarachnoid Hemorrhage - cerebrospinal fluid, Point-of-Care Systems, Luminescence, Interleukin-6 - cerebrospinal fluid, Enzyme-Linked Immunosorbent Assay
781 10
Editorial
01 May 2023 : Editorial
Editorial: Twenty Years On from Sequencing the Human Genome, Personalized/Precision Oncology Prepares to Meet the Challenges of Checkpoint Inhibitor TherapyDOI: 10.12659/MSM.940911
Med Sci Monit 2023; 29:e940911
In Press
31 May 2023 : Review article
Prevalence, Diagnosis, and Management of Eclampsia and the Need for Improved Maternal Care: A ReviewMed Sci Monit In Press; DOI: 10.12659/MSM.939919
30 May 2023 : Clinical Research
A Case-Control Study of Cognitive Function in Patients with End-Stage Renal Disease Before and After Hemodi...Med Sci Monit In Press; DOI: 10.12659/MSM.940409
30 May 2023 : Review article
A Review of the Role of the Zebrafish (Danio reiro) in Preclinical and Clinical Models of Biomarker Identif...Med Sci Monit In Press; DOI: 10.12659/MSM.940550
30 May 2023 : Database Analysis
The COVID-19 Crisis and the Incidence of Alcohol-Related Deaths in PolandMed Sci Monit In Press; DOI: 10.12659/MSM.940904
Most Viewed Current Articles
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952